CDC recommends use of Johnson & Johnson’s Janssen COVID-19 vaccine resume

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Apr. 30, 2021
  
  What you need to know:
  
  • CDC and the U.S. Food and Drug Administration (FDA) recommend use of Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine resume in the United States, after a temporary pause.
  
  • Reports of adverse events following the use of J&J/Janssen vaccine suggest an increased risk of a rare adverse event called thrombosis with thrombocytopenia syndrome (TTS). Nearly all reports of this serious condition, which involves blood clots with low platelets, have been in adult women younger than 50 years old.
  
  • A review of all available data at this time shows that the J&J/Janssen COVID-19 Vaccine’s known and potential benefits outweigh its known and potential risks.
  
  • However, women younger than 50 years old should be aware of the rare but increased risk of this adverse event and that there are other COVID-19 vaccine options available for which this risk has not been seen.
  
  • CDC and FDA will continue to monitor the safety of all COVID-19 vaccines.
  
  • Seek medical care right away if you develop any of the symptoms below after receiving the J&J/Janssen COVID-19 Vaccine.
  
  • If you have any questions or concerns, call your doctor, nurse, or clinic.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines Patient Safety Viral Vaccines
• Document Type:
  Webpage
• Name as Subject:
  Janssen COVID-19 vaccine
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:ddc38c9d1be3eecc18668ca61c066fea15599c12c751ba06b02c1b49a87b92f1
• Download URL:
  https://stacks.cdc.gov/view/cdc/105680/cdc_105680_DS1.pdf
• File Type:
  [PDF - 171.90 KB ]